SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending strongly as the community celebrates its strategic decision to withdraw from a major acquisition, avoiding significant debt and receiving a substantial breakup fee, which is perceived as a disciplined move to boost shareholder value.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp is trending as escalating geopolitical tensions in the Middle East fuel widespread speculation about an imminent surge in oil prices and the potential for a massive short squeeze. The community is actively discussing the company's recent debt reduction and improved financial standing, positioning it as a significant oil play amidst market uncertainty.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar is trending as it secures significant equity investments, bolstering liquidity amidst plans for its largest model offensive to date, sparking optimism among some investors about a turnaround. However, community discussions remain divided, with many expressing skepticism over the company's long-term profitability and stock performance, especially following its recent reverse split and revised sales targets.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd. is trending as escalating geopolitical tensions regarding potential US military action against Iran drive strong community speculation about a significant rally in oil prices. Traders are keenly watching for a potential short squeeze, given the company's low float and historical responsiveness to such global events, with upcoming drilling news also adding to the bullish outlook.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending amid high anticipation for founder Dr. Patrick Soon-Shiong's prime-time interviews and an upcoming investor conference call, with the community speculating on major updates for ANKTIVA and catalysts that could trigger a significant short squeeze.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is experiencing a surge in investor interest following strong financial results that significantly exceeded expectations, alongside positive pipeline updates for its long-acting navenibart program. The community is actively discussing the company's renewed profitability, potential for growth in rare-disease therapies, and the possibility of a short squeeze given high trading volume and notable short interest.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is generating buzz after its AXPAXLI Phase 3 trial demonstrated superiority against Eylea for wet AMD, but an unexpected stock decline has sparked community debate over the drug's commercial differentiation against newer therapies and its safety profile, intensifying persistent buyout speculation.

Hawaiian Electric Industries, Inc. is a holding company, which engages in electric utility and non-regulated renewable and sustainable infrastructure businesses. The company was founded by C. Dudley Pratt Jr. in 1981 and is headquartered in Honolulu, HI.

Hawaiian Electric Industries, Inc.

Hawaiian Electric is trending as investors digest its Q4 2025 earnings, showcasing a notable recovery, while closely tracking ongoing wildfire settlement progress and related legal developments. Community discussion is vibrant, with many anticipating a return to pre-fire valuations and dividend reinstatement, although some express caution regarding potential short-term pullbacks despite significant institutional accumulation.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar Corporation is trending as investors closely watch for an anticipated SpaceX IPO, fueled by reports of SpaceX's $800 billion valuation and plans to line up banks for a potential March 2026 public offering. The community is actively discussing EchoStar's substantial equity stake in SpaceX, viewing it as the most direct public proxy for gaining exposure to the private space company, alongside EchoStar's strategic spectrum sales and strengthened financial position.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics (AAOI) is trending after reporting an earnings beat and strong guidance, fueled by surging demand for its 800G transceivers in AI and cloud data centers. However, a significant stock offering has ignited a fierce debate in the community between bulls anticipating further gains and skeptics warning of unsustainable valuation and potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evolent to Participate in Upcoming Investor Conferences

Evolent to Participate in Upcoming Investor Conferences Evolent to Participate in Upcoming Investor Conferences PR Newswire WASHINGTON, Feb. 26, 2026 WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent...

Evolent Health (NYSE:EVH) Price Target Lowered to $4.00 at Citigroup

Citigroup lowered their price objective on shares of Evolent Health from $6.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday...

UBS Group Lowers Evolent Health (NYSE:EVH) Price Target to $5.00

UBS Group reduced their price objective on shares of Evolent Health from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday...

Evolent Health (NYSE:EVH) Price Target Lowered to $4.00 at Needham & Company LLC

Needham & Company LLC lowered their price target on shares of Evolent Health from $15.00 to $4.00 and set a "buy" rating on the stock in a report on Wednesday...

Royal Bank Of Canada Cuts Evolent Health (NYSE:EVH) Price Target to $3.00

Royal Bank Of Canada reduced their target price on shares of Evolent Health from $5.00 to $3.00 and set a "sector perform" rating for the company in a research report on Wednesday...

KeyCorp Downgrades Evolent Health (NYSE:EVH) to Sector Weight

KeyCorp lowered shares of Evolent Health from an "overweight" rating to a "sector weight" rating in a report on Wednesday...

BTIG Research Issues Pessimistic Forecast for Evolent Health (NYSE:EVH) Stock Price

BTIG Research cut their price objective on Evolent Health from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday...

Evolent Health Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

<ul class="summary-bullets"><li>The company’s EBITDA forecast of around $110 million to $140 million falls short of its FY2025 EBITDA of $151.2 million.</li><li>Evolent’s Q4 revenue fell 27% to $468.7 million, but beat estimates of $467.5 million, according to Fiscal.ai data.</li><li>Keybanc sees Evolent’s debt leverage rising to about seven times before potentially moderating.</li></ul>Shares of Evolent Health (EVH) fell more than 5% in pre-market trading on Wednesday, following a bearish brokerage action after the company announced lower earnings guidance alongside its fourth-quarter results.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/EVH">EVH stock</a> would fall to an all-time low. This adds to the heavy selling pressure over the past month, during which the shares have slumped 31%.The company also generated significant retail buzz. According to Stocktwits data, message volume on the platform increased by 1,850% over the past 24 hours and by 1,200% over the past seven days.<h2 class="st-heading-2">Q4 Revenue Beats Estimates Despite 27% Drop</h2>Evolent’s fourth-quarter revenue declined 27% to $468.7 million, but came in just over Wall Street’s estimates of $467.5 million, according to Fiscal.ai data. On an adjusted basis, the company reported earnings of $0.08 per share, beating consensus estimates of $0.05 per share.Evolent forecasts full-year 2026 revenue to be in the range of $2.4 billion to $2.6 billion, above the $1.88 billion revenue it reported in FY 2025. However, its adjusted earnings before interest, tax, depreciation and amortization (EBITDA) forecast of around $110 million to $140 million falls short of its FY2025 EBITDA of $151.2 million.“While the addition of $900 million in new Performance Suite revenue in 2026, as well as the impact of significant health plan customer membership decreases in their Exchange products, create an impact on Adjusted EBITDA in the first half of the year, we believe our year-end 2026 margins should quickly step-up as new contract reserving effects ease throughout the year and our operating cost reduction plan ramps up across 2026,” CEO Seth Blackley said.<h2 class="st-heading-2">Keybanc Flags Lack Of Visibility In EBITDA Recovery&nbsp;</h2>KeyBanc downgraded Evolent Health to ‘Sector Weight’ from ‘Overweight’ without adding a price target, according to The Fly. Although the firm described Evolent’s Q4 results as ‘solid’, KeyBanc had expected the company’s debt leverage to begin easing in early 2026. Instead, the brokerage sees leverage rising to about seven times before potentially moderating later in 2026.Keybanc also added that the downgrade reflects “limited visibility into a meaningful EBITDA recovery in the near term.”“While this increase in revenue creates a powerful foundation for EBITDA acceleration, it also creates a temporary headwind in 2026 due to our reserving methodologies and the timing of implementation of the new contracts. Second, Specialty TNS 2026 performance is experiencing a significant headwind from exchange membership declines consistent with the entire industry,” CFO Mario Ramos said in a call with analysts.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the pre-market fall, retail sentiment turned ‘neutral’ from ‘bearish’ a day earlier, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/EVH_jpg_11849304d8.webp" alt="EVH.jpg">One user said the stock’s decline doesn’t reflect its fair value.<stembedurl>https://stocktwits.com/BPler/message/645782444</stembedurl>Another user does not expect the stock price to drop any further.<stembedurl>https://stocktwits.com/PHILMYWALLET/message/645787843</stembedurl>The stock has been in an extended downtrend, declining more than 34% so far in 2026 and over 75% in the past year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-subdued-nvda-nflx-wbd-unh-lcid-wulf-stocks-to-watch/cZRUzKuR46j">Nasdaq, S&amp;P 500 Futures Subdued Ahead Of Nvidia Earnings: Why WBD, NFLX, UNH, LCID, WULF Are On Traders' Radar Today</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Evolent Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

EVH Stock On Track To Open At Record Low – Here’s Why Keybanc Turned Cautious 

KeyBanc downgraded Evolent Health to ‘Sector Weight’ from ‘Overweight’, citing a lack of visibility in near-term EBITDA recovery.

Equity

Evolent Health Q4 Earnings Call Highlights

Evolent Health (NYSE:EVH) reported fourth-quarter results that landed in the upper half of management's guidance range, as leadership emphasized continued momentum across organic growth...

$EVH Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$3.84 down -1322.22% YoY
• Evolent Health expects full year 2026 revenue to range from $2.4B to $2.6B and Adjusted EBITDA to be between $110M and $140M, reflecting strong customer retention.

Stocktwits

Evolent Health Inc - Ordinary Shares - Class A

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$3.84 down -1322.22% YoY
• Evolent Health expects full year 2026 revenue to range from $2.4B to $2.6B and Adjusted EBITDA to be between $110M and $140M, reflecting strong customer retention.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Evolent Health, Inc. engages in the provision of healthcare delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

EVH
Evolent Health Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EVH News

EVHEvolent Health Inc - Ordinary Shares - Class A